查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1930123

全球麻疹-腮腺炎-德国麻疹 (MMR) 疫苗市场：市场规模、市场占有率、成长率、产业分析、类型、应用和区域分析、未来预测 (2026-2034)

Measles, Mumps, Rubella (MMR) Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 请询问到货日

价格

麻疹-腮腺炎-德国麻疹 (MMR) 疫苗市场成长驱动因子

由于疾病发生率上升、疫苗接种覆盖率扩大以及全球各国政府的持续支持，全球麻疹-腮腺炎-德国麻疹 (MMR) 疫苗市场正经历显着增长。根据 Fortune Business Insights 的数据显示，2025 年全球 MMR 疫苗市场规模为 51.7 亿美元。预计该市场将从 2026 年的 55.9 亿美元成长到 2034 年的 144.3 亿美元，预测期内复合年增长率 (CAGR) 为 12.59%。 预计到2025年，北美将以38.02%的市场占有率引领全球市场，这主要得益于强有力的疫苗接种计划和高接种率。

麻疹、腮腺炎和德国麻疹是传染性极强且可能危及生命的病毒性疾病。麻疹、腮腺炎、德国麻疹合併疫苗（MMR疫苗）是一种含有减毒活病毒的联合疫苗，通常分两剂接种，分别在12个月和4岁时接种。这些疫苗的高效性、强烈的免疫原性反应和长期保护作用使其成为许多国家国家免疫计画的重要组成部分。

市场动态

市场驱动因素

政府主导的措施和疫苗接种计划的扩展是推动麻疹、腮腺炎、德国麻疹联合疫苗市场发展的关键因素。美国和印度等国家已将麻疹、腮腺炎、德国麻疹联合疫苗纳入其国家免疫规划（NIP），确保民众能够免费或享有补助接种。 世界卫生组织 (WHO)、联合国儿童基金会 (UNICEF) 和全球疫苗免疫联盟 (Gavi) 等国际组织的支持显着扩大了疫苗覆盖范围。根据美国疾病管制与预防中心 (CDC) 称，截至 2025 年 1 月，单剂麻疹、腮腺炎、德国麻疹 (MMR) 疫苗对麻疹的有效率为 93.0%，对腮腺炎的有效率为 72%，对德国麻疹的有效率为 97%，这增强了人们对该疫苗有效性的信心。

市场限制因子

疫苗犹豫仍是限制市场成长的主要因素。错误讯息、宗教信仰和对副作用的担忧等因素降低了疫苗的接受度。 2023 年发布的一份报告指出，家长担心接种疫苗后会出现发烧和注射部位疼痛，导致某些人延迟接种疫苗。

市场机会

技术进步，特别是微阵列贴片 (MAP) 的开发，带来了可观的成长机会。 这些无针、耐热的给药系统提高了患者的依从性，简化了疫苗接种流程，尤其是在中低收入国家。联合国儿童基金会和世界卫生组织积极支持MAP的研发，该系统展现出巨大的未来潜力。

市场挑战

维持冷链仍然是一项重大挑战。麻疹、腮腺炎、德国麻疹疫苗对温度高度敏感，不当的储存和运输会导致疫苗浪费和效力降低。偏远地区薄弱的冷链基础设施持续阻碍市场的最佳扩张。

市场趋势

影响市场的关键趋势是公私合作的兴起。政府、非政府组织和製药公司之间的合作正在提高疫苗的可及性，加强供应链，并弥补免疫接种缺口。全球麻疹疫情的再次爆发正在推动进一步的协调疫苗接种工作。

市场区隔分析

依类型

2024年，联合疫苗因其便利性、成本效益和减少注射负担而占市场主导地位。麻疹-腮腺炎-德国麻疹二联疫苗（MMR II）和普利乐（PRIORIX）等产品有助于提高患者依从性。同时，单联疫苗因其针对特定疾病的用途而维持了相当大的市场占有率。

依产品

2024年，麻疹-腮腺炎-德国麻疹二联疫苗（MMR II）占最大的市场占有率，这得益于其数十年的使用历史以及在各国免疫规划中的广泛应用。普利乐（PRIORIX）由于获得美国FDA批准并在100多个国家获得许可，预计将实现强劲成长。

依给药途径

2024年，皮下注射因其监管建议和患者舒适度而占市场主导地位。 由于其强大的免疫原性和不断扩大的批准范围，肌注给药途径也保持了相当大的市场占有率。

依年龄组别划分

由于强制性儿童疫苗接种计划，儿科市场占主导地位。成人市场也稳定成长，这得益于未接种疫苗或部分接种疫苗的成年人意识的提高。

依通路划分

由于国家疫苗接种计划的大规模采购，政府供应商在2024年占了最大的市场占有率。随着疫苗接种点的增加，医院和零售药局预计将显着成长。

区域展望

北美地区得益于高疫苗接种率和健全的公共卫生基础设施，预计2025年和2026年的收入将分别达到19.7亿美元和21.5亿美元。

由于欧盟/欧洲经济区国家实施强制性两剂疫苗接种制度，欧洲仍占较大占有率。

亚太地区预计将实现最快成长，这得益于庞大的人口基数和政府资助的疫苗接种计划，尤其是在印度。

拉丁美洲和中东/非洲地区由于公众意识的提高和疫苗可及性的改善，正经历稳步增长。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键考虑因素

  • 主要国家和地区主要疾病的发生率/盛行率（2025 年）
  • 主要公司产品线分析
  • 主要国家疫苗接种覆盖率概览
  • 麻疹、腮腺炎、德国麻疹 (MMR) 疫苗技术进展
  • 主要公司新产品发布
  • 主要产业趋势：併购、业务合作等等。

第五章 全球麻疹-腮腺炎-德国麻疹 (MMR) 疫苗市场分析：洞察与预测 (2021-2034)

  • 市场分析、洞察与预测：依类型
    • 单价疫苗
    • 联合疫苗
  • 市场分析、洞察与预测：依产品
    • MMR II
    • PRIORIX
    • MMR Pro
    • Tresivac
    • 其他
  • 市场分析、洞察与预测：依给药途径
    • 肌肉注
    • 皮下注射
    • 其他
  • 市场分析、洞察与预测：依年龄组别
    • 儿科
    • 成人
  • 市场分析、洞察与预测：依通路划分
    • 医院和零售药局
    • 政府供应商
    • 其他
  • 市场分析、洞察与预测：依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美麻疹-腮腺炎-德国麻疹 (MMR) 疫苗市场分析：洞察与预测 (2021-2034)

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲麻疹-腮腺炎-德国麻疹 (MMR) 疫苗市场分析：洞察与预测 (2021-2034)

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章 亚太地区麻疹-腮腺炎-德国麻疹 (MMR) 疫苗市场分析：洞察与预测 (2021-2034)

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章：拉丁美洲麻疹-腮腺炎-德国麻疹 (MMR) 疫苗市场分析：洞察与预测 (2021-2034)

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章：中东与非洲麻疹-腮腺炎-德国麻疹 (MMR) 疫苗市场分析：洞察与预测 (2021-2034)

  • 依国家划分
    • 海湾合作委员会 (GCC) 国家
    • 南非
    • 中东和非洲其他地区

第十一章 竞争分析

  • 全球市占率分析 (2025)
  • 公司公司简介
    • GSK plc.
    • Serum Institute of India Pvt. Ltd.
    • Merck &Co., Inc.
    • Indian Immunologicals Limited
    • Zydus Lifesciences Limited
    • Takeda Pharmaceutical Company Limited
    • BIOLOGICAL E. LIMITED
    • Invivyd, Inc.
    • Daiichi Sankyo Company, Limited
Product Code: FBI113753

Growth Factors of measles, mumps, rubella (MMR) vaccines Market

The global measles, mumps, rubella (MMR) vaccines market is witnessing strong expansion due to rising disease incidence, growing immunization coverage, and sustained government support worldwide. According to Fortune Business Insights, the global MMR vaccines market size was valued at USD 5.17 billion in 2025. The market is projected to grow from USD 5.59 billion in 2026 to USD 14.43 billion by 2034, registering a CAGR of 12.59% during the forecast period. North America dominated the global market with a share of 38.02% in 2025, supported by robust immunization programs and high vaccine uptake.

Measles, mumps, and rubella are highly contagious and potentially life-threatening viral diseases. MMR vaccines are combination vaccines containing live attenuated viruses, administered in two doses-typically at 12 months and again at 4 years of age. The high potency, strong immunogenic response, and long-term protection offered by these vaccines have made them essential components of national immunization schedules across multiple countries.

Market Dynamics

Market Drivers

Rising government initiatives and immunization programs are major drivers of the MMR vaccines market. Countries such as the U.S. and India have incorporated MMR vaccines into their National Immunization Programs (NIP), ensuring free or subsidized access. Support from international organizations such as WHO, UNICEF, and Gavi has significantly expanded vaccine coverage. According to the CDC, as of January 2025, one dose of the MMR vaccine is 93.0% effective against measles, 72% against mumps, and 97% against rubella, reinforcing strong confidence in vaccine effectiveness.

Market Restraints

Vaccine hesitancy remains a key restraint limiting market growth. Factors such as misinformation, religious beliefs, and fear of side effects reduce vaccine acceptance. Reports published in 2023 highlighted parental concerns regarding post-vaccination fever and injection-site pain, which continue to delay immunization in certain populations.

Market Opportunities

Technological advancements, particularly the development of microarray patches (MAPs), offer promising growth opportunities. These needle-free, thermostable delivery systems improve patient compliance and simplify vaccine administration, especially in low- and middle-income countries. UNICEF and WHO have actively supported MAP development, indicating strong future potential.

Market Challenges

Cold chain maintenance remains a critical challenge. MMR vaccines are highly temperature-sensitive, and improper storage or transportation can lead to vaccine wastage and reduced efficacy. Weak cold chain infrastructure in remote regions continues to hinder optimal market expansion.

Market Trends

A key trend shaping the market is the rise in public-private partnerships. Collaboration between governments, NGOs, and pharmaceutical companies is improving vaccine accessibility, strengthening supply chains, and addressing immunization gaps. Increasing measles resurgence globally has further intensified coordinated immunization efforts.

Segmentation Analysis

By Type

The combination vaccine segment dominated the market in 2024 due to convenience, cost-effectiveness, and reduced injection burden. Products such as M-M-R II and PRIORIX support higher patient compliance. The standalone segment maintained a notable share due to disease-specific usage.

By Product

M-M-R II held the largest market share in 2024, driven by decades-long usage and widespread inclusion in national immunization programs. PRIORIX is expected to grow at a strong pace due to U.S. FDA approval and licensing across more than 100 countries.

By Route of Administration

The subcutaneous route dominated the market in 2024, supported by regulatory recommendations and patient comfort. The intramuscular segment also held a significant share due to strong immunogenicity and expanded approvals.

By Age Group

The pediatric segment led the market owing to mandatory childhood vaccination schedules. The adult segment is growing steadily as awareness increases among unvaccinated or partially vaccinated adults.

By Distribution Channel

Government suppliers accounted for the largest share in 2024 due to large-scale procurement for national immunization programs. Hospital and retail pharmacies are expected to grow significantly with expanding vaccination access points.

Regional Outlook

North America generated revenues of USD 1.97 billion in 2025 and USD 2.15 billion in 2026, driven by high vaccination coverage and strong public health infrastructure.

Europe maintained a significant share due to mandatory two-dose schedules across EU/EEA countries.

Asia Pacific is witnessing the fastest growth, supported by large population bases and government-funded vaccination programs, particularly in India.

Latin America and the Middle East & Africa are growing steadily with increasing awareness and improved vaccine access.

Competitive Landscape

The market is led by GSK plc., Merck & Co., Inc., and Serum Institute of India Pvt. Ltd., supported by strong R&D pipelines and global distribution networks. Other prominent players include Indian Immunologicals Limited, Zydus Lifesciences Limited, Takeda Pharmaceutical Company Limited, and Biological E. Limited.

Conclusion

In conclusion, the global measles, mumps, rubella (MMR) vaccines market is set for robust growth from 2025 to 2034, expanding from USD 5.17 billion in 2025 to USD 14.43 billion by 2034. Strong government initiatives, high vaccine efficacy, and expanding immunization coverage are key growth drivers. However, vaccine hesitancy and cold chain challenges remain critical concerns. Continued innovation, public-private collaboration, and investment in advanced delivery technologies will be essential to sustaining long-term market growth.

Segmentation By Type

  • Standalone
  • Combination

By Product

  • M-M-R II
  • PRIORIX
  • M-M-RvaxPro
  • Tresivac
  • Others

By Route of Administration

  • Intramuscular
  • Subcutaneous
  • Others

By Age Group

  • Adult
  • Pediatric

By Distribution Channel

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

By Region

  • North America (By Type, Product, Route of Administration, Age Group, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Type, Product, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Type, Product, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Type, Product, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Type, Product, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Incidence/Prevalence of Key Diseases, By Key Countries/Regions, 2025
  • 4.2. Pipeline Analysis, By Key Players
  • 4.3. Overview: Immunization Coverage, By Key Countries
  • 4.4. Technological Advancements in the MMR Vaccines
  • 4.5. New Product Launches, By Key Players
  • 4.6. Key Industry Developments Such as Mergers, Acquisitions, and Partnerships

5. Global Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Standalone
    • 5.1.2. Combination
  • 5.2. Market Analysis, Insights and Forecast - By Product
    • 5.2.1. M-M-R II
    • 5.2.2. PRIORIX
    • 5.2.3. M-M-RvaxPro
    • 5.2.4. Tresivac
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Intramuscular
    • 5.3.2. Subcutaneous
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Age Group
    • 5.4.1. Pediatrics
    • 5.4.2. Adults
  • 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.5.1. Hospital & Retail Pharmacies
    • 5.5.2. Government Suppliers
    • 5.5.3. Others
  • 5.6. Market Analysis, Insights and Forecast - By Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Standalone
    • 6.1.2. Combination
  • 6.2. Market Analysis, Insights and Forecast - By Product
    • 6.2.1. M-M-R II
    • 6.2.2. PRIORIX
    • 6.2.3. M-M-RvaxPro
    • 6.2.4. Tresivac
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Intramuscular
    • 6.3.2. Subcutaneous
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Age Group
    • 6.4.1. Pediatrics
    • 6.4.2. Adults
  • 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.5.1. Hospital & Retail Pharmacies
    • 6.5.2. Government Suppliers
    • 6.5.3. Others
  • 6.6. Market Analysis, Insights and Forecast - By Country
    • 6.6.1. U.S.
    • 6.6.2. Canada

7. Europe Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Standalone
    • 7.1.2. Combination
  • 7.2. Market Analysis, Insights and Forecast - By Product
    • 7.2.1. M-M-R II
    • 7.2.2. PRIORIX
    • 7.2.3. M-M-RvaxPro
    • 7.2.4. Tresivac
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Intramuscular
    • 7.3.2. Subcutaneous
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Age Group
    • 7.4.1. Pediatrics
    • 7.4.2. Adults
  • 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.5.1. Hospital & Retail Pharmacies
    • 7.5.2. Government Suppliers
    • 7.5.3. Others
  • 7.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.6.1. U.K.
    • 7.6.2. Germany
    • 7.6.3. France
    • 7.6.4. Spain
    • 7.6.5. Italy
    • 7.6.6. Scandinavia
    • 7.6.7. Rest of Europe

8. Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Standalone
    • 8.1.2. Combination
  • 8.2. Market Analysis, Insights and Forecast - By Product
    • 8.2.1. M-M-R II
    • 8.2.2. PRIORIX
    • 8.2.3. M-M-RvaxPro
    • 8.2.4. Tresivac
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Intramuscular
    • 8.3.2. Subcutaneous
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Age Group
    • 8.4.1. Pediatrics
    • 8.4.2. Adults
  • 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.5.1. Hospital & Retail Pharmacies
    • 8.5.2. Government Suppliers
    • 8.5.3. Others
  • 8.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. Australia
    • 8.6.5. Southeast Asia
    • 8.6.6. Rest of Asia Pacific

9. Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Standalone
    • 9.1.2. Combination
  • 9.2. Market Analysis, Insights and Forecast - By Product
    • 9.2.1. M-M-R II
    • 9.2.2. PRIORIX
    • 9.2.3. M-M-RvaxPro
    • 9.2.4. Tresivac
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Intramuscular
    • 9.3.2. Subcutaneous
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By Age Group
    • 9.4.1. Pediatrics
    • 9.4.2. Adults
  • 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.5.1. Hospital & Retail Pharmacies
    • 9.5.2. Government Suppliers
    • 9.5.3. Others
  • 9.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.6.1. Brazil
    • 9.6.2. Mexico
    • 9.6.3. Rest of Latin America

10. Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Standalone
    • 10.1.2. Combination
  • 10.2. Market Analysis, Insights and Forecast - By Product
    • 10.2.1. M-M-R II
    • 10.2.2. PRIORIX
    • 10.2.3. M-M-RvaxPro
    • 10.2.4. Tresivac
    • 10.2.5. Others
  • 10.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.3.1. Intramuscular
    • 10.3.2. Subcutaneous
    • 10.3.3. Others
  • 10.4. Market Analysis, Insights and Forecast - By Age Group
    • 10.4.1. Pediatrics
    • 10.4.2. Adults
  • 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.5.1. Hospital & Retail Pharmacies
    • 10.5.2. Government Suppliers
    • 10.5.3. Others
  • 10.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.6.1. GCC
    • 10.6.2. South Africa
    • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. GSK plc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Serum Institute of India Pvt. Ltd.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Merck & Co., Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Indian Immunologicals Limited
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Zydus Lifesciences Limited
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Takeda Pharmaceutical Company Limited
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. BIOLOGICAL E. LIMITED
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Invivyd, Inc.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Daiichi Sankyo Company, Limited
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 2: Global Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 3: Global Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 4: Global Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 5: Global Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 6: Global Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 7: North America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 8: North America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 9: North America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 10: North America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 11: North America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: North America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 13: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 14: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 15: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 16: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 17: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 18: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 19: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 20: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 21: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 22: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 23: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 25: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 26: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 27: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 28: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 29: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 30: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 31: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 32: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 33: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 34: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 35: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 36: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Measles, Mumps, Rubella (MMR) Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Type, 2025 & 2034
  • Figure 3: Global Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 4: Global Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Age Group, 2025 & 2034
  • Figure 5: Global Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Product, 2025 & 2034
  • Figure 6: Global Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 7: Global Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Region, 2025 & 2034
  • Figure 8: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 9: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Type, 2025
  • Figure 10: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 11: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 12: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 13: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Age Group, 2025
  • Figure 14: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Product, 2025 & 2034
  • Figure 15: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Product, 2025
  • Figure 16: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 17: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 18: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Country, 2025 & 2034
  • Figure 19: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Country, 2025
  • Figure 20: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 21: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Type, 2025
  • Figure 22: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 23: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 24: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 25: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Age Group, 2025
  • Figure 26: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Product, 2025 & 2034
  • Figure 27: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Product, 2025
  • Figure 28: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 29: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 30: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 31: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 32: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 33: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Type, 2025
  • Figure 34: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 35: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 36: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 37: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Age Group, 2025
  • Figure 38: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Product, 2025 & 2034
  • Figure 39: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Product, 2025
  • Figure 40: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 41: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 42: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 43: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 44: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 45: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Type, 2025
  • Figure 46: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 47: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 48: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 49: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Age Group, 2025
  • Figure 50: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Product, 2025 & 2034
  • Figure 51: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Product, 2025
  • Figure 52: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 53: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 54: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 55: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 56: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 57: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Type, 2025
  • Figure 58: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 59: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 60: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 61: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Age Group, 2025
  • Figure 62: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Product, 2025 & 2034
  • Figure 63: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Product, 2025
  • Figure 64: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 65: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 66: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 67: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 68: Global Measles, Mumps, Rubella (MMR) Vaccines Market Share (%), By Company, 2025